Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited announced U.S. Food and Drug Administration approval of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous ...

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the most recent TreatmentTrends ®: Multiple ...

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration. Sep. 05, 2024 4:05 PM ET Amneal Pharmaceuticals, Inc. (AMRX) ...